Sector News

India plans drug industry foreign investment scorecard

May 31, 2016
Life sciences

India’s Commerce and Industry Ministry plans to measure the impact of foreign investment on the drug industry in a step that will be closely watched for any conclusions for–or against–more activity in the sector.

The Times of India said the move to hire unnamed academics to conduct the study was prompted over concerns that investments to date have been in existing companies instead of the hoped-for Greenfield projects.

A committee in India’s lower house of parliament has suggested banning foreign investment in existing firms and a stronger look at even new ventures, the Times of India said.

“In many countries, takeovers are not allowed in strategic sectors like pharma. For India, affordable healthcare is a challenge and for that access to medicines is important,” the newspaper said, quoting an unnamed industry expert.

India does allow up to 100% of foreign direct investment in existing drug companies and new operations, although this is subject to competition and other regulatory approvals.

The study also comes as segments of India’s mainly generic-driven drug industry catch more attention in the M&A space from companies abroad.

That includes China’s Shanghai Fosun Pharmaceuticals, which said in mid-May it was in the race to buy unlisted Hyderabad-based injectables maker Gland Pharma, joining Baxter International and buyout firm Advent International, for a company valued at around $1.5 billion.

Domestically, the industry is still dominated by players like Sun Pharmaceutical Industries–the world’s fifth largest generic firm which bought Ranbaxy Laboratories in 2014 from Japan’s Daiichi Sankyo.

The report on the impact of foreign investment is slated to be finished in three to four months, according to the Times of India, adding that the impact of investment on access to low-cost drugs and related patent rules would also be a focus.

Civil groups have questioned recent moves to uphold patents in cases that called into question access to drugs or effective originality. Indian generic drugmakers have also called on the government to ensure they can continue to challenge patents under existing laws.

By EJ Lane

Source: Fierce Pharma

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach